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Available online 30 July 2016Background: Experimental and clinical evidence indicate that inﬂammatory processes in atherogenesis and the
development of cardiovascular complications are promoted by a loss of regulatory T cell (Treg)-mediated immu-
nological tolerance to plaque antigens. Yet, the association between alterations of systemic Treg frequency and
cardiovascular disease incidence remains uncertain.
Methods: A nested case-cohort study was conducted within the European Prospective Investigation into Cancer
and Nutrition (EPIC)-Heidelberg, comprising a random subcohort (n=778) and primary cases ofmyocardial in-
farction (MI, n = 276) and ischemic stroke (n= 151). Pre-diagnostic FOXP3+ Treg and total CD3+ T-lympho-
cyte (tTL) frequencies in blood were measured by epigenetic-based, quantitative real-time PCR-assisted cell
counting.
Results:Multivariate, Prentice-weighted Cox regression analyses revealed that lower Treg/tTL ratios were not as-
sociatedwith the risk of either MI (lowest vs. highest sex-speciﬁc quartile; hazard ratio: 0.72, 95% conﬁdence in-
terval: 0.46 to 1.13; Ptrend = 0.51) or stroke (HR: 0.90, 95% CI: 0.51 to 1.60; Ptrend = 0.78). There were no
correlations of Treg/tTL ratios with C-reactive protein, HbA1c, and various lipid parameters.
Conclusions: Among middle-aged adults from the general population, imbalances in the relative frequency of
Tregs within the total T cell compartment do not confer an increased risk of MI or stroke.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cardiovascular disease risk1. Introduction
Progression and rupture of atherosclerotic plaques in coronary and
carotid arteries are important pathogenic factors in the development
of myocardial and cerebral infarctions (Falk et al., 2013; Qureshi and
Caplan, 2014). Inﬂammatory processes in the arterial intima play a
key role in all stages of atherogenesis (Hansson, 2005; Hansson and
Hermansson, 2011) and are strongly modulated by functionally distinct
T cell subsets (Ammirati et al., 2015). Accumulating evidence suggests
that such inﬂammation may partly develop owing to reduced immune
tolerance, which leads to autoimmune-like responses targeted against
plaque antigens (Nilsson and Hansson, 2008; Matsuura et al., 2014).
The best documented epitopes capable of activating autoreactive T
cells or the generation of autoantibodies are derived from oxidizedth), r.kaaks@dkfz-heidelberg.de
atzke@dkfz-heidelberg.de
), janika.schulze@epiontis.com
kfz-heidelberg.de (T. Kühn).
. This is an open access article underlow-density lipoproteins (oxLDL) (Nilsson et al., 2009) and heat shock
proteins (Almanzar et al., 2012;Wick et al., 2014), but also loss of toler-
ance against unmodiﬁed self-proteins, such as apolipoprotein B100, has
been found (Nilsson et al., 2012). In healthy persons, escape from pe-
ripheral self-tolerance and perturbed immune homeostasis are limited
by regulatory T cells (Tregs), which implicates dysregulation of Tregs
in atherosclerotic disease (Sakaguchi et al., 2010).
There is evidence from animal models that Tregs exhibit
atheroprotective properties by suppression of autoreactive T cell re-
sponses or by secretion of anti-inﬂammatory cytokines (Pastrana et
al., 2012). The potential importance of Tregs to cardiovascular disorders
in humans was supported by histological studies showing reduced Treg
frequencies or their functional defects in human atherosclerotic lesions
compared to stable plaques andnormal vessel tissue fragments (de Boer
et al., 2007; Dietel et al., 2013). Therefore, therapeutic strategies aimed
at treating or preventing cardiovascular disease (CVD) by enhancement
of physiological immunosuppression have attracted growing interest in
recent years, as reviewed in (Meng et al., 2016). However, data are
mainly pre-clinical and promising anti-atherogenic effects through vac-
cination against LDL-derived antigens cannot be solely ascribed to athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Tregs have been observed in patients with acute coronary syndromes
(ACS) compared to patients with stable angina in several studies (Han
et al., 2007; Cheng et al., 2008; Mor et al., 2006), while others reported
a Treg increase in patientswith ST-elevation acutemyocardial infarction
(MI) and a Treg decrease in non-ST elevation ACS patients (Ammirati et
al., 2010). Irrespective of these ﬁndings, there is a lack of data on pre-di-
agnostic Treg frequencies in blood and CVD risk from prospective stud-
ies. In the only study so far addressing the potential role of circulating
Treg levels in the etiology of human CVD, blood levels of CD4+FoxP3+
T cells were associated with a higher incidence of MI (Wigren et al.,
2012). Yet, this study did not reveal an association of Tregs with stroke
incidence and comprised a small, elderly population with a very high
prevalence of hypertension. Thus, it remains uncertain as towhether al-
terations in the circulating Treg compartment represent a consequence
of disease manifestation or may be a pre-disposing risk factor reﬂecting
a global immune imbalance (Caligiuri and Nicoletti, 2010).
One core obstacle of epidemiological studies on Tregs and CVD risk is
that a ﬂow cytometry-based measurement of immune cells generally
requires fresh whole blood samples. In addition, Tregs currently lack
speciﬁc cell surfacemarkers in humans. Originally, Tregswere identiﬁed
and characterized by their expression of CD4, forkhead box protein P3
(FOXP3) and CD25. More recently, stable expression of FOXP3 in Tregs
was found to be largely controlled by a highly conserved CpG-enriched
element in the FOXP3 gene, the Treg-speciﬁc demethylated region
(TSDR) in mice (Floess et al., 2007) and conﬁrmed in humans. Since ac-
tivated human conventional CD4+ T cells can also express CD25 and
FOXP3 (Wang et al., 2007) whereas TSDR demethylation is not shared
by activated T cells (Baron et al., 2007), the Treg-speciﬁc epigenetic sta-
tus provides themost accurate identiﬁcation and quantiﬁcation of Tregs
(Morikawa and Sakaguchi, 2014). Indeed, Tregs constitute a stable cell
lineage, whose state is ensured by DNA demethylation of the Foxp3
locus irrespectively of ongoing Foxp3 expression (Miyao et al., 2012).
Using such an epigenetic approach, it has been recently conﬁrmed
that reduced Treg frequencies in the circulation, deﬁned by enhanced
TSDRmethylation, are associated with disease severity in male patients
with ACS comparedwith normal coronary controls (Jia et al., 2013; Lü et
al., 2013). In a similar manner, we have also established the epigenetic
pattern of the CD3 locus as quantitative measurement system for total
CD3+ T-lymphocytes (tTLs) (Sehouli et al., 2011) and showed that
the ratio of Tregs to tTLs constitutes a clinically relevant parameter of
immune tolerance (Turbachova et al., 2013).
In the present study, we aimed at evaluating the relationship be-
tween the Treg/tTL ratio in blood of initially healthy individuals and
the risk of MI and stroke in a case-cohort study nested within the Euro-
pean Prospective Investigation into Cancer andNutrition (EPIC)-Heidel-
berg cohort. Cell-type speciﬁc epigenetic assays based on DNA
demethylation analysis were applied for immune cell quantiﬁcation in
archived pre-diagnostic leukocyte samples of incident CVD cases and
controls. Subsequently, we investigated if low Treg/tTL ratios are associ-
ated with an increased CVD risk.
2. Materials and Methods
2.1. Study Population
The European Prospective Investigation into Cancer and Nutrition
(EPIC) - Heidelberg study was initiated as part of the Europe-wide
EPIC project and includes 11,929 male and 13,611 female participants
aged 35 to 65 years that were recruited from the local general popula-
tion. Baseline examinations were carried out from 1994 through 1998
and included blood sampling, anthropometric measurements and self-
administered questionnaires on diet, lifestyle and reproductive health.
The study was conducted in compliance with standards indicated by
the Declaration of Helsinki. All participants gave written informed con-
sent and the study protocol was approved by the ethics committee ofthe Medical School of the University of Heidelberg (Riboli et al., 2002;
Boeing et al., 1999). Incident cases of MI and stroke were ascertained
through follow-up questionnaires at regular intervals of about three
years, and all reported cases were validated by study physicians against
medical records. The following cardiovascular events of interest were
coded according to the International Classiﬁcation of Diseases, 10th ver-
sion, 2015 (ICD-10): myocardial infarction (I21); ischemic stroke (I63).
Further details on follow-up procedures of EPIC-Heidelberg have been
described elsewhere (Bergmann et al., 1999).
For the present analyses, an unstratiﬁed case-cohort study design
was used. After exclusion of prevalent CVD cases among subcohort
members (n = 16), the study population comprised primary cases of
myocardial infarction (MI, n = 346) and ischemic stroke (n = 187)
that occurred between baseline examination and December 31, 2007
as well as a random subcohort of 835 individuals. This subcohort was
initially drawn for the EPIC-InterAct case-cohort study on diabetes,
and thus did only include participants without a history of diabetes
(Langenberg et al., 2011). Consequently, incident cases of MI (n = 47)
and stroke (n= 21), who had reported to have diabetes at the baseline
of the EPIC-Heidelberg study were excluded from the present analyses
as well. Given the possibility of tumor-mediated changes in peripheral
immune cell type fractions, we further excluded participants with prev-
alent cancer (MI: n = 14; Stroke: n = 13, Non-cases: n = 38). Study
participants were also excluded when quality control in quantitative
PCR (qPCR) analysis failed (MI: n = 5, Stroke: n = 1, Non-cases: n =
6) or there were missing covariate data (MI: n = 4, Stroke: n = 1,
Non-cases: n = 13). Thus, statistical analyses were performed based
on data of 276 cases of MI, 151 cases of stroke, and 778 subcohortmem-
bers. The randomly selected subcohort eventually included twenty-two
incident CVD cases (MI: n = 11, Stroke: n = 11). Details on the ﬁnal
sample are illustrated in Supplementary Fig. 1.
2.2. Laboratory Methods
At baseline recruitment into the EPIC-Heidelberg cohort, 30 ml of
blood was taken from all cohort participants using anticoagulant (cit-
rate) containing monovettes at room temperature and centrifuged for
20 min at 1500 ×g. Buffy coats were separated from the interphase
and aliquoted into 500 μl portions which were stored in liquid nitrogen
in the EPIC-Heidelberg biobank. Genomic DNA was isolated through
proprietary extraction methods by Laboratory of the Government
Chemist Limited (LGC Limited, Hoddesdon, UK). DNA solutions for
each subject were stored at −80 °C until DNA analyses took place.
DNA concentration and qualitywasmeasured usingQuant-iT PicoGreen
dsDNA Assay (Life Technologies, Darmstadt, Germany).
Epigenetic-based quantiﬁcation of Tregs and tTLs was carried out by
Epiontis GmbH (Berlin, Germany), as previously reported (Barth et al.,
2015). Brieﬂy, using bisulﬁte converted DNA as substrate, qPCR-Assays
were performed for the selected cell type-speciﬁc demethylated loci -
the Treg-speciﬁc demethylated region (TSDR) in FOXP3 gene and the
CD3g/d intergenic region - and for a locus known to be demethylated
in all cell types (GAPDH) (Sehouli et al., 2011). The latter was used to
allow for determination of total leukocytes. For the present analyses,
data of epigenetic-based cell counts are presented as the percentage
share of TSDR demethylation divided by CD3 locus demethylationwith-
in peripheral blood leukocyte DNA samples by multiplying that ratio by
one hundred. The Treg/tTL ratiowas then used as amarker of peripheral
immune tolerance.
In addition, routine clinical biochemistry markers were analyzed at
the SHL Laboratories (Etten-Leur, Netherlands). Straws were opened
using a heated wire cutting system followed by aliquoting directly
intomeasurement tubes. Serum and erythrocyte sampleswere then de-
livered to the SHL group on dry ice. Serum concentrations of lipid pa-
rameters and HbA1c from erythrocytes were determined using the
Roche Cobas 6000 analytical system for clinical chemistry according to
the manufacturer's protocols.
Table 1
Baseline characteristics and laboratory parameters of the study population: EPIC Heidel-
berg case-cohort study.
MI cases
(N = 276)
Stroke cases
(N = 151)
Subcohort
(N = 778)
Male sex (N, %) 219 (79)⁎ 96 (64)⁎ 355 (46)
Age at blood draw (years) 55.6 ± 6.3⁎ 55.6 ± 7.1⁎ 50.6 ± 8.0
Age at diagnosis (years) 60.7 ± 6.9 60.6 ± 7.8 –
University degree (N, %) 66 (24)⁎ 39 (26) 244 (31)
Physically inactive (N, %) 42 (15) 25 (17) 89 (11)
BMI (kg/m2) 27.9 ± 4.0⁎ 27.3 ± 3.9⁎ 25.7 ± 4.2
Lifetime alcohol intake (g/day) 24.9 ± 30.5⁎ 22.2 ± 29.3⁎ 16.8 ± 24.4
Red and processed meat intake
≥ 120 g/day (N, %)a
96 (35)⁎ 43 (28) 170 (22)
Smoking status (N, %)
Never smokers 85 (31) 48 (32) 338 (43)
Former smokers ≥ 10 years 55 (20) 37 (25) 175 (22)
Former smokers b 10 years 23 (8) 13 (9) 84 (11)
Current smokers b 15 cig/day 28 (10) 13 (9) 79 (10)
Current smokers ≥ 15 cig/day 85 (31)⁎ 40 (26)⁎ 102 (13)
Hyperlipidemia (N, %)b 145 (53)⁎ 76 (50)⁎ 263 (34)
Use of lipid-lowering drugs (N, %)c 42 (29) 19 (25) 66 (25)
Hypertension (N,%)b 126 (46)⁎ 71 (47)⁎ 209 (27)
Use of anti-hypertensive
drugs (N, %)c
92 (73) 51 (72) 134 (64)
Use of NSAIDs (N, %)b 33 (12) 17 (11) 68 (9)
Use of calcium supplements (N, %)b 13 (5)⁎ 4 (3) 16 (2)
Laboratory measurements of T cell
subsets (median, range)
% CD3+ tTL of leukocytes 19.7
(3.9–48.7)
19.9
(8.6–41.5)
20.0
(4.0–61.3)
% Foxp3+ Treg cells of leukocytes 1.0 (0.3–3.1) 1.0 (0.3–2.4) 1.0 (0.2–4.9)
Treg/tTL ratiod 5.2 (1.7–14.0) 5.1 (1.8–12.0) 5.1 (1.5–15.5)
BMI: bodymass index. NSAIDs: non-steroidal anti-inﬂammatory drugs. tTL: total CD3+T-
lymphocytes.
Values are means ± standard deviation or percentages unless otherwise stated.
Data are missing for lipid-lowering (n = 2) medication.
a Adjusted for total energy intake using the residual method.
b Prevalent.
c Among individuals with prevalent hypertension or hyperlipidemia, respectively.
d Ratio multiplied by 100.
⁎ P b 0.05 for case vs. subcohort. P-value for difference was calculated using the chi-
squared test for categorical variables and the t-test for continuous variables.
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Baseline characteristics of individualswith andwithout incident car-
diovascular disease are presented as means ± standard deviations or
proportions. Differences between means of continuous variables were
assessed by t-tests, and differences in proportions between cases and
non-cases were assessed by chi-squared tests. Measurements of T cell
subsets are displayed asmedians with minimum andmaximum values.
Spearman's rank correlation coefﬁcients adjusted for age, smoking sta-
tus (never, former, current) and stratiﬁed by sex were used to assess
the strengths of associations between waist circumference, BMI,
glycated hemoglobin (HbA1c), various lipoprotein–lipid parameters
and epigenetic cell counts. Treg/tTL ratios were categorized into quar-
tiles according to sex-speciﬁc values in the subcohort and individuals
in the highest quartile were considered as the reference group. Pren-
tice-weighted Cox proportional hazards regression models with age at
baseline as the underlying time-scale were used to assess the risk for in-
cidence of a primary cardiovascular event between Treg quartiles
(Prentice, 1986). All observations in the subcohort were left-truncated
at age at baseline and censored at end of follow-up, death or loss to fol-
low-up, whichever came ﬁrst. Following the Prentice-weighting-
scheme, risk sets at a particular event time are composed of allmembers
of the subcohort at risk and cases at that event time, who were only in-
cluded into the risk set shortly before their event. To adjust for age dif-
ferences in cases at study entry and other potential age-cohort effects,
all analyses were stratiﬁed by integer values (in years) of age at base-
line. The extended correlation test based on Schoenfeld residuals (Xue
et al., 2013) did not indicate any violations to the proportional hazards
assumption.
Sex-adjusted and multivariable-adjusted hazard ratios (HRs) along
with their 95% conﬁdence intervals (CIs) were estimated. Identiﬁcation
of potential confounders was based on a priori literature search and all
those factors were selected that changed the risk estimates by N10%,
orwere associatedwith the exposure. Thus, the following potential con-
founders were additionally included in a uniform multivariable-adjust-
ed model: body mass index (BMI, kg/m2), physical activity (inactive,
moderately inactive, moderately active and active), smoking status
(never smokers, former smokers quitting ≥10 years, former smokers
quitting b10 years, current smokers b 15 cigarettes per day, current
smokers ≥ 15 cigarettes per day), baseline alcohol intake (g/day), use
of calcium supplements (yes or no), energy-adjusted dietary intakes
of red and processed meat (g/day), and prevalent hypertension or hy-
perlipidemia at recruitment (yes or no). Potential confounding was
also evaluated, but not found, for the following variables: highest educa-
tional level, lifetime alcohol intake, regular use of antihypertensive or
lipid-lowering drugs, and use of non-steroidal anti-inﬂammatory drugs.
The ratio of Tregs to tTLs followed an approximately log-normal dis-
tribution. Tests for linear trend were carried out based on continuous
Treg values on the log2 scale, thus calculating the HR associated with
a halving of the Treg/tTL ratio. Sensitivity analyses were conducted ex-
cluding cases that were diagnosed within the ﬁrst 2 years of follow-
up. Finally, multiplicative statistical interactions with risk factors were
tested for by including cross-product terms along with the main effect
terms into the multivariable adjusted models. All statistical tests were
2-sided and P-values below 0.05 were considered to indicate statistical
signiﬁcance. All statistical analyses were performed with SAS 9.3 (SAS
Institute, Cary, NC).
3. Results
3.1. Participant Characteristics
Median follow-up time for the study populationwas 7.2 years± 2.7.
The mean age at diagnosis was 60.7 ± 6.9 years for individuals with in-
cident MI and 60.6 ± 7.8 years among those with incident stroke. The
vast majority of cases of MI (N = 218 out of 276) and stroke (N =142 out of 151) were non-fatal within 28 days of admission. Socio-de-
mographic and life-style characteristics for all study participants are
shown in Table 1. Brieﬂy, both endpoints were more common in men
(MI: 79%; Stroke: 64%) than women. As compared to the subcohort, in-
dividuals who had an incident cardiovascular event were older and had
a higher prevalence of established cardiovascular risk factors, including
heavy smoking, adiposity, hypertension, and hyperlipidemia. Therewas
no signiﬁcant difference in the frequency of lipid-lowering medication,
anti-hypertensive drugs, or calcium supplement use between cases
and subcohort members.
In the subcohort, there were fewer individuals in the lowest com-
pared to the highest quartile of Treg/tTL ratios who have reported to
be current smokers, used anti-hypertensive drugs or NSAIDS (Supple-
mentary Table 1). Other potential confounders such as age, education
levels, BMI, waist circumference and physical activity were equally dis-
tributed across quartiles of Treg/tTL ratios. Finally, high-sensitive C-re-
active protein, HbA1c, and lipid parameters did not correlate with the
Treg/tTL ratio in the subcohort (Supplementary Table 2).
3.2. Association Between Treg/tTL Ratios and CVD Risk
The distribution of T cell subpopulations across cases of MI, stroke
and non-cases is visualized by jittered boxplots in Supplementary Fig.
2. Prospective associations between Treg/tTL ratios in blood and the
risk of MI and stroke are shown in Table 2. In Cox models stratiﬁed by
age and adjusted for sex, lower peripheral Treg/tTL ratioswere associat-
edwith a reduced risk ofMI (lowest vs. highest quartile; HR=0.62, 95%
CI = 0.41 to 0.95; Ptrend = 0.04). However, this association was
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ple cardiovascular risk factors were included in Cox regression models
(HR= 0.72, 95% CI = 0.46 to 1.13, Ptrend = 0.51). No signiﬁcant associ-
ationswere observed for ischemic stroke, with amultivariable-adjusted
hazard ratio between extreme quartiles of 0.90 (95% CI = 0.51 to 1.60;
Ptrend = 0.78).
Sensitivity analyses by excluding cases that occurred within the ﬁrst
2 years since blood draw (MI: n = 46, Stroke: n = 27) yielded results
that were consistent with those of ourmain analyses; the fully adjusted
HR (95% CI) of MI and stroke, respectively, was 0.68 (95% CI = 0.42 to
1.09, Ptrend= 0.41) and 0.91 (95% CI= 0.49 to 1.68, Ptrend= 0.71) com-
paring extreme quartiles of the Treg/tTL ratio. Interactions between red
meat intake on a continuous scale and Treg/tTL ratios were observed
with respect to both MI and stroke risk (MI: Pinteraction = 0.02; Stroke:
Pinteraction = 0.01). Additionally, there was a signiﬁcant trend for inter-
action between smoking - categorized as never, former, current
smokers - and Tregs in Cox regression analyses on MI (Pinteraction =
0.045), but not stroke. Multivariable-adjusted subgroup analyses that
were stratiﬁed according to strata of sex-speciﬁc redmeat intake tertiles
showed no signiﬁcant associations with MI or stroke risk across the risk
strata (data not shown). In contrast, a statistically signiﬁcant inverse
trend inMI risk across quartiles of Treg/tTL ratios was found among for-
mer smokers in multivariable-adjusted models (HRlog2 = 0.56, 95%
CI = 0.31 to 0.99, Ptrend = 0.047), but not current or never smokers
(Supplementary Table 3).
4. Discussion
In the present population-based study, we assessed the relationship
between pre-diagnostic Treg to tTL ratios and future cardiovascular
events using a highly speciﬁc epigenetic assay for the quantiﬁcation of
T cell subsets. After a median follow-up time of about 7 years, lower
Treg/tTL ratios were not associated with either an increased incidence
of myocardial infarction or ischemic stroke in multivariable models ac-
counting for traditional risk factors of atherosclerotic CVD. These ﬁnd-
ings do not support a potential role of altered Treg-mediated immune
tolerance as a risk factor for human CVD.
Previous studies in humanswere centered almost exclusively on pa-
tients with established cardiovascular disease and therefore it remained
uncertain whether reduced circulating levels of Tregs are an important
etiological factor, or rather reﬂect facilitated Treg trafﬁcking to ischemic
tissues as part of regulatory mechanisms involved in resolution of post-
infarction inﬂammatory response (Frangogiannis, 2012). In accordance
with a protective role of Tregs in CVDdevelopment, theMalmöDiet and
Cancer Study cardiovascular cohort (MDCS-CV) study showed that low
circulating Treg levels, deﬁned as CD4+FoxP3+ T cells, wereTable 2
Hazard ratios (95% conﬁdence intervals) for incident cardiovascular events by sex-speciﬁc qua
Outcome Quartilesc
1 (high) 2 3
6.4/7.4 5.1/6.0 4.3/5.1
Myocardial infarction
N cases/subcohort 97/194 63/195 61/195
Sex-adjusteda 1.00 0.71 (0.47, 1.08) 0.71 (0.4
MV-adjustedb 1.00 0.58 (0.37, 0.93) 0.86 (0.5
Ischemic stroke
N cases/subcohort 47/194 30/195 41/195
Sex-adjusteda 1.00 0.76 (0.45, 1.26) 0.95 (0.5
MV-adjustedb 1.00 0.66 (0.37, 1.19) 1.14 (0.6
a Derived from Prentice-weighted Cox proportional-hazards regression with age as underly
b The hazard ratio in multivariable (MV) models was additionally adjusted for the following
status, body mass index, physical activity, baseline alcohol intake, energy-adjusted dietary inta
c Quartile cut-points, displayed as medians in men/women, were based on the distribution
d Tests for linear trendwere carried out based on the continuous values of Treg/tTL ratios on
models.associated with an increased risk for acute myocardial infarction (haz-
ard ratio 1.9 for the lowest Treg tertile) during a 15-year follow-up.
On the contrary, no association of Treg frequencies with overall stroke
risk was found (Wigren et al., 2012). Our results for ischemic stroke
are in agreement with these ﬁndings byWigren and colleagues, where-
as absence of an association between low Treg/tTL ratios and MI risk
contrasts with their results. However, the present study differs from
theMDCS-CV study in several respects.We used an epigenetic approach
for immune cell quantiﬁcation as compared with a cytokine release
assay combined with ﬂow cytometry in the previous study. This differ-
ence may be relevant because Tregs form only a minor fraction of lym-
phocytes in blood and epigenetic signatures involving the FOXP3 TSDR
demethylation status are currently considered to be the most speciﬁc
marker of stable Tregs (Floess et al., 2007; Polansky et al., 2008; Baron
et al., 2007). An earlier comparison between quantiﬁcation of Treg/tTL
ratios in cord and adult blood samples using epigenetic qPCR and ﬂow
cytometry assays showed reasonable method agreement, even though
it has to be noted that differences to some degree between the two
methods can be expected as the epigenetic tool allows a more speciﬁc
detection of functionally stable FOXP3+ Tregs compared to surface
marker-based ﬂow cytometry (Nettenstrom et al., 2013). Besides the
different assays applied in the present study and the study by Wigren
et al., deviating denominators used to determine relative Treg frequen-
cies (CD3+ T cells in EPIC-Heidelberg vs. CD4+ T cells in theMDCS-CV
study) must be considered when making a direct comparison of results
from the two studies. In fact, there may be differences in the directions
of associations between distinct T cell subpopulations, such as CD4+
and CD8+ T cells, with inﬂammatory and autoimmune-mediated path-
ogenesis of atherosclerotic CVD (Ammirati et al., 2015), and
CD3+CD8+ T cells were positively associated with MI risk in the
MDCS-CV study (Kolbus et al., 2013).Moreover, EPIC-Heidelberg cohort
participants included here were free of diabetes (0% vs. 21% and 11%
among cases and controls from theMDCS-CV), younger (mean baseline
age 55 years vs. 65 years), and incident MI cases had less frequently re-
ported hypertension at baseline (46% vs. 87%) compared to the MDCS-
CV study. In contrast, MI cases occurredmore frequently inmen as com-
paredwith those cases identiﬁed in theMDCS-CV (79% vs. 53%). Of note,
male gender, increasing age aswell as other established CVD risk factors
such as diabetes and arterial hypertension have all been proposed to be
inversely associated with absolute Treg numbers (Kornete et al., 2013;
Idris-Khodja et al., 2014). Inconsistency of results between both studies
may thus be due to heterogeneity concerning the cardiovascular risk
proﬁle, and could imply that the role of circulating Tregs in CVD devel-
opment depends on the extent or type of pre-existing arterial remodel-
ing. Further clariﬁcation of this issue will require veriﬁcation in other
cohorts including atherosclerosis imaging approaches.rtiles of the Treg/tTL ratio.
HR (95% CI)log2 Ptrendd
4 (low)
3.2/4.1
55/194
7, 1.08) 0.62 (0.41, 0.95) 0.70 (0.50, 0.98) 0.04
5, 1.33) 0.72 (0.46, 1.13) 0.88 (0.60, 1.29) 0.51
33/194
9, 1.54) 0.77 (0.46, 1.29) 0.78 (0.52, 1.17) 0.23
8, 1.89) 0.90 (0.51, 1.60) 0.94 (0.59, 1.48) 0.78
ing time variable, stratiﬁed by age at baseline (in 1-year categories), and adjusted for sex.
traditional risk factors: presence or absence of hypertension or hyperlipidemia, smoking
kes of red and processed meat, use of calcium supplements.
in the female and male subcohort.
the log2 scale, whichwere included alongwith themain effect terms into theMV-adjusted
155S.D. Barth et al. / EBioMedicine 11 (2016) 151–156It could be argued that the lack of association between pre-diagnos-
tic Treg/tTL ratios and CVD risk in the present study is due to the fact
that plaques represent a different immunological compartment than
blood (Grivel et al., 2011), and it remains to be determined whether
Treg levels in blood adequately reﬂect sustained immune responses in
the arterial wall. Actually, a correlation of circulating Tregs with the ca-
rotid intima-media thickness, a proxy of subclinical atherosclerosis,
could not be found in both healthy populations (Wigren et al., 2012;
Ammirati et al., 2010) and ACS patients (Ammirati et al., 2010). Never-
theless, it is increasingly acknowledged that antigen-speciﬁc atherogen-
ic T cell responses are initiated in secondary lymphoid organs by
presentation of plaque antigens (Ammirati et al., 2015) and a systemic
nature of immune reactions related to atherosclerosis is further sup-
ported by the fact that both local and systemic inﬂammation affect
early steps of atherogenesis and CVD (Hansson, 2005). In a previous
study, we have also shown that higher pre-diagnostic Treg/tTL ratios
in blood are associated with the risk of lung, colorectal and ER-Negative
breast cancer (Barth et al., 2015). These observations support the rele-
vance of Tregs in the periphery to local immune homeostasis and
tolerance.
Another potentially important result of this study is that CVD risk
across quartiles of Treg to tTL ratios was attenuated on adjustment for
smoking, which is in line with previous data demonstrating that both
acute and cumulative smoking exposure positively correlates with the
Treg/tTL ratio (Wiencke et al., 2012). Although largely unknown, a
smoking-associated Treg increase in blood may either reﬂect a more
general state of suppressed immune and inﬂammatory responses
(Stampﬂi and Anderson, 2009; Shiels et al., 2014) or relates to facilitated
mobilization andmigration of Tregs to tissue sites affected by smoke ex-
posure to dampen local inﬂammation (Ritter et al., 2005). In fact, our
subgroup analyses by smoking status did point to some heterogeneity
in the associations between Treg frequencies and MI but not stroke
risk. With respect to MI, a signiﬁcant inverse association with Treg fre-
quencieswas only observed in former smokers,while therewere no sig-
niﬁcant associations in current and never smokers. Admittedly, our
subgroup samples were rather small and possible smoking-related in-
ﬂuences on the relationship between peripheral Treg variability and
MI risk may require further study in a larger sample.
The strengths of our study include its prospective design, the large
sample size for our main analyses, and the use of epigenetic assays,
which enable the quantiﬁcation of immune cells in buffy coat samples
after long-term storage. There are also some limitations to this study
that have to be considered. First, the generalizability of the association
between cellular immune markers and CVD development is limited to
some extent because the EPIC-Heidelberg cohort represents a popula-
tion with a higher socio-economic status and more favorable lifestyle
factor proﬁle compared to populations from other regions in Germany
(Boeing et al., 1999). This overrepresentation of health-conscious indi-
viduals could have become even more pronounced by restriction of
our investigation to non-diabetics. With regard to the quantiﬁcation of
overall Tregs, it must be noted that we could not address the issue of
heterogeneity within the Treg compartment in our study and that dif-
ferent T cell subsets may have distinct properties in CVD development.
Our study was set up to analyze Treg-mediated immune tolerance as a
global phenomenon, but studies on more speciﬁc functions of immune
cell subsets are clearly needed. Another general limitation of long-
term observational studies is that exposures aremeasured only at a sin-
gle point in time. However, in a reproducibility study of 100 healthy
EPIC-Heidelberg participants with repeated measurements, we have
previously shown amoderate-high correlation between individual's pe-
ripheral Treg/tTL ratio over time periods of one year (r = 0.73) and up
to ﬁfteen years (r = 0.53) (Barth et al., 2015). Thus, a single quantiﬁca-
tion may provide a good proxy for long-term FOXP3+ Treg values and
supports the notion that relative numbers of these cells in the periphery
are kept in a homeostatic state throughout life (Liston and Gray, 2014;
Fessler et al., 2013).In conclusion, we observed no association between pre-diagnostic
Treg to tTL ratios in peripheral blood and future cardiovascular events
in a cohort of non-diabetic, middle-aged individuals. Unlike previous
ﬁndings from experimental studies and a smaller epidemiological
study in elderly individuals, our results do not indicate that lower Treg
frequencies in peripheral blood, as assessed relative to total T cells, are
a risk factor of CVD.
Funding Sources
This work was supported by the German Federal Ministry of Educa-
tion and Research (BMBF), Grant number 01ER0809 and the German
Cancer Research Center (DKFZ Heidelberg, Germany). Biomarker analy-
ses were provided by Epiontis, Berlin. Sven Olek was supported by the
German FederalMinistry of Education andResearch (BMBF), KMU Inno-
vative, Grant number 031A191A (EpiLyze). The funders were not in-
volved in writing the manuscript or the decision to submit it for
publication. The authors of this manuscript did not receive further
funding by a pharmaceutical company.
Conﬂicts of Interest
Sven Olek is an employee and owner of Epiontis, Berlin, a company
that develops epigenetic assays. Janika Schulze and Katharina Gellhaus
are employees of Epiontis, Berlin. Sven Olek holds patents on assays
for the quantiﬁcation of Foxp3+ and CD3+ T cells. The other authors
declare that they have no competing ﬁnancial interest.
Author Contributions
RK and SO conceived and designed the study. SO coordinated the
laboratory analyses.
TJ prepared the samples. JS performed the laboratory analyses with
support fromKG. SB analyzed the data. TK and VK veriﬁed the statistical
analyses. SB wrote and TK revised the manuscript. All authors critically
revised and approved the ﬁnal version of the manuscript.
Appendix A. Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.07.035.
References
Almanzar, G., Ollinger, R., Leuenberger, J., Onestingel, E., Rantner, B., Zehm, S., Cardini, B.,
Van Der Zee, R., Grundtman, C., Wick, G., 2012. Autoreactive HSP60 epitope-speciﬁc
T-cells in early human atherosclerotic lesions. J. Autoimmun. 39, 441–450.
Ammirati, E., Cianﬂone, D., Banﬁ, M., Vecchio, V., Palini, A., De Metrio, M., Marenzi, G.,
Panciroli, C., Tumminello, G., Anzuini, A., Palloshi, A., Grigore, L., Garlaschelli, K.,
Tramontana, S., Tavano, D., Airoldi, F., Manfredi, A.A., Catapano, A.L., Norata, G.D.,
2010. Circulating CD4+CD25hiCD127lo regulatory T-cell levels do not reﬂect the ex-
tent or severity of carotid and coronary atherosclerosis. Arterioscler. Thromb. Vasc.
Biol. 30, 1832–1841.
Ammirati, E., Moroni, F., Magnoni, M., Camici, P.G., 2015. The role of T and B cells in
human atherosclerosis and atherothrombosis. Clin. Exp. Immunol. 179, 173–187.
Baron, U., Floess, S., Wieczorek, G., Baumann, K., Grützkau, A., Dong, J., Thiel, A., Boeld, T.J.,
Hoffmann, P., Edinger, M., Türbachova, I., Hamann, A., Olek, S., Huehn, J., 2007. DNA
demethylation in the human FOXP3 locus discriminates regulatory T cells from acti-
vated FOXP3+ conventional T cells. Eur. J. Immunol. 37, 2378–2389.
Barth, S.D., Schulze, J.J., Kuhn, T., Raschke, E., Husing, A., Johnson, T., Kaaks, R., Olek, S.,
2015. Treg-mediated immune tolerance and the risk of solid cancers: ﬁndings from
EPIC-Heidelberg. J. Natl. Cancer Inst. 107.
Bergmann, M.M., Bussas, U., Boeing, H., 1999. Follow-up procedures in EPIC-
Germany—data quality aspects. European Prospective Investigation into Cancer and
Nutrition. Ann Nutr Metab 43, 225–234.
Boeing, H., Korfmann, A., Bergmann, M.M., 1999. Recruitment procedures of EPIC-Germa-
ny. European Investigation into Cancer and Nutrition. Ann. Nutr. Metab. 43, 205–215.
Caligiuri, G., Nicoletti, A., 2010. Tregs and human atherothrombotic diseases: toward a
clinical application? Arterioscler. Thromb. Vasc. Biol. 30, 1679–1681.
Cheng, X., Yu, X., Ding, Y.-J., Fu, Q.-Q., Xie, J.-J., Tang, T.-T., Yao, R., Chen, Y., Liao, Y.-H., 2008.
The Th17/Treg imbalance in patients with acute coronary syndrome. Clin. Immunol.
127, 89–97.
156 S.D. Barth et al. / EBioMedicine 11 (2016) 151–156De Boer, O.J., Van Der Meer, J.J., Teeling, P., Van Der Loos, C.M., Van Der Wal, A.C., 2007.
Low numbers of FOXP3 positive regulatory T cells are present in all developmental
stages of human atherosclerotic lesions. PLoS One 2, e779.
Dietel, B., Cicha, I., Voskens, C.J., Verhoeven, E., Achenbach, S., Garlichs, C.D., 2013. De-
creased numbers of regulatory T cells are associated with human atherosclerotic le-
sion vulnerability and inversely correlate with inﬁltrated mature dendritic cells.
Atherosclerosis 230, 92–99.
Falk, E., Nakano, M., Bentzon, J.F., Finn, A.V., Virmani, R., 2013. Update on acute coronary
syndromes: the pathologists' view. Eur. Heart J. 34, 719–728.
Fessler, J., Ficjan, A., Duftner, C., Dejaco, C., 2013. The impact of aging on regulatory T-cells.
Front. Immunol. 4, 231.
Floess, S., Freyer, J., Siewert, C., Baron, U., Olek, S., Polansky, J., Schlawe, K., Chang, H.D.,
Bopp, T., Schmitt, E., Klein-Hessling, S., Serﬂing, E., Hamann, A., Huehn, J., 2007. Epige-
netic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5, e38.
Frangogiannis, N.G., 2012. Regulation of the inﬂammatory response in cardiac repair. Circ.
Res. 110, 159–173.
Grivel, J.C., Ivanova, O., Pinegina, N., Blank, P.S., Shpektor, A., Margolis, L.B., Vasilieva, E.,
2011. Activation of T lymphocytes in atherosclerotic plaques. Arterioscler. Thromb.
Vasc. Biol. 31, 2929–2937.
Han, S.F., Liu, P., Zhang, W., Bu, L., Shen, M., Li, H., Fan, Y.H., Cheng, K., Cheng, H.X., Li, C.X.,
Jia, G.L., 2007. The opposite-direction modulation of CD4+CD25+ Tregs and T help-
er 1 cells in acute coronary syndromes. Clin. Immunol. 124, 90–97.
Hansson, G.K., 2005. Inﬂammation, atherosclerosis, and coronary artery disease. N. Engl.
J. Med. 352, 1685–1695.
Hansson, G.K., Hermansson, A., 2011. The immune system in atherosclerosis. Nat.
Immunol. 12, 204–212.
Idris-Khodja, N., Mian, M.O., Paradis, P., Schiffrin, E.L., 2014. Dual opposing roles of adap-
tive immunity in hypertension. Eur. Heart J. 35, 1238–1244.
Jia, L., Zhu, L., Wang, J.Z., Wang, X.J., Chen, J.Z., Song, L., Wu, Y.J., Sun, K., Yuan, Z.Y., Hui, R.,
2013. Methylation of FOXP3 in regulatory T cells is related to the severity of coronary
artery disease. Atherosclerosis 228, 346–352.
Kolbus, D., Ljungcrantz, I., Andersson, L., Hedblad, B., Fredrikson, G.N., Björkbacka, H.,
Nilsson, J., 2013. Association between CD8+ T-cell subsets and cardiovascular dis-
ease. J. Intern. Med. 274, 41–51.
Kornete, M., Mason, E.S., Piccirillo, C.A., 2013. Immune regulation in T1D and T2D: pro-
spective role of Foxp3+ Treg cells in disease pathogenesis and treatment. Front.
Endocrinol. (Lausanne) 4, 76.
Langenberg, C., Sharp, S., Forouhi, N.G., Franks, P.W., Schulze, M.B., Kerrison, N., Ekelund,
U., Barroso, I., Panico, S., Tormo, M.J., Spranger, J., Grifﬁn, S., Van Der Schouw, Y.T.,
Amiano, P., Ardanaz, E., Arriola, L., Balkau, B., Barricarte, A., Beulens, J.W., Boeing, H.,
Bueno-De-Mesquita, H.B., Buijsse, B., Chirlaque Lopez, M.D., Clavel-Chapelon, F.,
Crowe, F.L., De Lauzon-Guillan, B., Deloukas, P., Dorronsoro, M., Drogan, D., Froguel,
P., Gonzalez, C., Grioni, S., Groop, L., Groves, C., Hainaut, P., Halkjaer, J., Hallmans, G.,
Hansen, T., Huerta Castano, J.M., Kaaks, R., Key, T.J., Khaw, K.T., Koulman, A.,
Mattiello, A., Navarro, C., Nilsson, P., Norat, T., Overvad, K., Palla, L., Palli, D.,
Pedersen, O., Peeters, P.H., Quiros, J.R., Ramachandran, A., Rodriguez-Suarez, L.,
Rolandsson, O., Romaguera, D., Romieu, I., Sacerdote, C., Sanchez, M.J., Sandbaek, A.,
Slimani, N., Sluijs, I., Spijkerman, A.M., Teucher, B., Tjonneland, A., Tumino, R., Van
Der, A.D., Verschuren, W.M., Tuomilehto, J., Feskens, E., McCarthy, M., Riboli, E.,
Wareham, N.J., 2011. Design and cohort description of the InterAct Project: an exam-
ination of the interaction of genetic and lifestyle factors on the incidence of type 2 di-
abetes in the EPIC Study. Diabetologia 54, 2272–2282.
Liston, A., Gray, D.H., 2014. Homeostatic control of regulatory T cell diversity. Nat Rev
Immunol 14, 154–165.
Lü, C.-X., Xu, R.-D., Cao, M., Wang, G., Yan, F.-Q., Shang, S.-S., Wu, X.-F., Ruan, L., Quan, X.-
Q., Zhang, C.-T., 2013. FOXP3 demethylation as a means of identifying quantitative
defects in regulatory T cells in acute coronary syndrome. Atherosclerosis 229,
263–270.
Matsuura, E., Atzeni, F., Sarzi-Puttini, P., Turiel, M., Lopez, L.R., Nurmohamed, M.T., 2014. Is
atherosclerosis an autoimmune disease? BMC Med. 12, 47.
Meng, X., Yang, J., Dong, M., Zhang, K., Tu, E., Gao, Q., Chen, W., Zhang, C., Zhang, Y., 2016.
Regulatory T cells in cardiovascular diseases. Nat. Rev. Cardiol. 13, 167–179.
Miyao, T., Floess, S., Setoguchi, R., Luche, H., Fehling, H.J., Waldmann, H., Huehn, J., Hori, S.,
2012. Plasticity of Foxp3(+) T cells reﬂects promiscuous Foxp3 expression in con-
ventional T cells but not reprogramming of regulatory T cells. Immunity 36, 262–275.
Mor, A., Luboshits, G., Planer, D., Keren, G., George, J., 2006. Altered status of
CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes.
Eur. Heart J. 27, 2530–2537.
Morikawa, H., Sakaguchi, S., 2014. Genetic and epigenetic basis of Treg cell development
and function: from a FoxP3-centered view to an epigenome-deﬁned view of natural
Treg cells. Immunol. Rev. 259, 192–205.Nettenstrom, L., Alderson, K., Raschke, E.E., Evans, M.D., Sondel, P.M., Olek, S., Seroogy,
C.M., 2013. An optimized multi-parameter ﬂow cytometry protocol for human T reg-
ulatory cell analysis on fresh and viably frozen cells, correlation with epigenetic anal-
ysis, and comparison of cord and adult blood. J. Immunol. Methods 387, 81–88.
Nilsson, J., Hansson, G.K., 2008. Autoimmunity in atherosclerosis: a protective response
losing control? J. Intern. Med. 263, 464–478.
Nilsson, J., Bjorkbacka, H., Fredrikson, G.N., 2012. Apolipoprotein B100 autoimmunity and
atherosclerosis - disease mechanisms and therapeutic potential. Curr. Opin. Lipidol.
23, 422–428.
Nilsson, J., Lichtman, A., Tegui, A., 2015. Atheroprotective immunity and cardiovascular
disease: therapeutic opportunities and challenges. J. Intern. Med.
Nilsson, J., Wigren, M., Shah, P.K., 2009. Regulatory T cells and the control of modiﬁed li-
poprotein autoimmunity-driven atherosclerosis. Trends Cardiovasc. Med. 19,
272–276.
Pastrana, J.L., Sha, X., Virtue, A., Mai, J., Cueto, R., Lee, I.A., Wang, H., Yang, X.F., 2012. Reg-
ulatory T cells and atherosclerosis. J. Clin. Exp. Cardiol. 2012, 2.
Polansky, J.K., Kretschmer, K., Freyer, J., Floess, S., Garbe, A., Baron, U., Olek, S., Hamann, A.,
Von Boehmer, H., Huehn, J., 2008. DNA methylation controls Foxp3 gene expression.
Eur. J. Immunol. 38, 1654–1663.
Prentice, R.L., 1986. A case-cohort design for epidemiologic cohort studies and disease
prevention trials. Biometrika 73, 1–11.
Qureshi, A.I., Caplan, L.R., 2014. Intracranial atherosclerosis. Lancet 383, 984–998.
Riboli, E., Hunt, K.J., Slimani, N., Ferrari, P., Norat, T., Fahey, M., Charrondiere, U.R., Hemon,
B., Casagrande, C., Vignat, J., Overvad, K., Tjonneland, A., Clavel-Chapelon, F., Thiebaut,
A., Wahrendorf, J., Boeing, H., Trichopoulos, D., Trichopoulou, A., Vineis, P., Palli, D.,
Bueno-De-Mesquita, H.B., Peeters, P.H., Lund, E., Engeset, D., Gonzalez, C.A.,
Barricarte, A., Berglund, G., Hallmans, G., Day, N.E., Key, T.J., Kaaks, R., Saracci, R.,
2002. European Prospective Investigation into Cancer and Nutrition (EPIC): study
populations and data collection. Public Health Nutr. 5, 1113–1124.
Ritter, M., Goggel, R., Chaudhary, N., Wiedenmann, A., Jung, B., Weith, A., Seither, P., 2005.
Elevated expression of TARC (CCL17) and MDC (CCL22) in models of cigarette
smoke-induced pulmonary inﬂammation. Biochem. Biophys. Res. Commun. 334,
254–262.
Sakaguchi, S., Miyara, M., Costantino, C.M., Haﬂer, D.A., 2010. FOXP3+ regulatory T cells
in the human immune system. Nat. Rev. Immunol. 10, 490–500.
Sehouli, J., Loddenkemper, C., Cornu, T., Schwachula, T., Hoffmuller, U., Grutzkau, A.,
Lohneis, P., Dickhaus, T., Grone, J., Kruschewski, M., Mustea, A., Turbachova, I.,
Baron, U., Olek, S., 2011. Epigenetic quantiﬁcation of tumor-inﬁltrating T-lympho-
cytes. Epigenetics 6, 236–246.
Shiels, M.S., Katki, H.A., Freedman, N.D., Purdue, M.P., Wentzensen, N., Trabert, B.,
Kitahara, C.M., Furr, M., Li, Y., Kemp, T.J., Goedert, J.J., Chang, C.M., Engels, E.A.,
Caporaso, N.E., Pinto, L.A., Hildesheim, A., Chaturvedi, A.K., 2014. Cigarette smoking
and variations in systemic immune and inﬂammation markers. J. Natl. Cancer Inst.
106.
Stampﬂi, M.R., Anderson, G.P., 2009. How cigarette smoke skews immune responses to
promote infection, lung disease and cancer. Nat. Rev. Immunol. 9, 377–384.
Turbachova, I., Schwachula, T., Vasconcelos, I., Mustea, A., Baldinger, T., Jones, K.A., Bujard,
H., Olek, A., Olek, K., Gellhaus, K., Braicu, I., Konsgen, D., Fryer, C., Ravot, E., Hellwag, A.,
Westerfeld, N., Gruss, O.J., Meissner, M., Hasan, M.T., Weber, M., Hoffmuller, U.,
Zimmermann, S., Loddenkemper, C., Mahner, S., Babel, N., Berns, E., Adams, R.,
Zeilinger, R., Baron, U., Vergote, I., Maughan, T., Marme, F., Dickhaus, T., Sehouli, J.,
Olek, S., 2013. The cellular ratio of immune tolerance (immunoCRIT) is a deﬁnite
marker for aggressiveness of solid tumors andmay explain tumor dissemination pat-
terns. Epigenetics 8, 1226–1235.
Wang, J., Ioan-Facsinay, A., Van Der Voort, E.I., Huizinga, T.W., Toes, R.E., 2007. Transient
expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur.
J. Immunol. 37, 129–138.
Wick, G., Jakic, B., Buszko, M., Wick, M.C., Grundtman, C., 2014. The role of heat shock pro-
teins in atherosclerosis. Nat. Rev. Cardiol. 11, 516–529.
Wiencke, J.K., Accomando, W.P., Zheng, S., Patoka, J., Dou, X., Phillips, J.J., Hsuang, G.,
Christensen, B.C., Houseman, E.A., Koestler, D.C., Bracci, P., Wiemels, J.L., Wrensch,
M., Nelson, H.H., Kelsey, K.T., 2012. Epigenetic biomarkers of T-cells in human glioma.
Epigenetics 7, 1391–1402.
Wigren, M., Bjorkbacka, H., Andersson, L., Ljungcrantz, I., Fredrikson, G.N., Persson, M.,
Bryngelsson, C., Hedblad, B., Nilsson, J., 2012. Low levels of circulating CD4+FoxP3+
T cells are associated with an increased risk for development of myocardial infarction
but not for stroke. Arterioscler. Thromb. Vasc. Biol. 32, 2000–2004.
Xue, X., Xie, X., Gunter, M., Rohan, T.E., Wassertheil-Smoller, S., Ho, G.Y., Cirillo, D., Yu, H.,
Strickler, H.D., 2013. Testing the proportional hazards assumption in case-cohort
analysis. BMC Med. Res. Methodol. 13, 88.
